A preferable signature of gut microbiota and bile acids predicted better outcomes of unresectable hepatocellular carcinoma to immune checkpoint inhibitors

被引：0
|
作者：
Lee, Pei-Chang [1 ]
Wu, Chijung [1 ]
Hung, Ya-Wen [1 ]
Lee, ChiehJu [1 ]
Chi, Chen-Ta [1 ]
Lee, I-Cheng [1 ]
Luo, Jiing-Chyuan [1 ]
Hou, Ming-Chih [1 ]
Huang, Yi-Hsiang [1 ]
机构：
[1] Taipei Vet Gen Hosp, Div Gastroenterol & Hepatol, Dept Med, Taipei, Taiwan
来源：
JOURNAL OF HEPATOLOGY | 2022年 / 77卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
OS160
引用
收藏
页码：S109 / S110
页数：2
相关论文
共 50 条
  • [1] Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma
    Lee, Pei-Chang
    Wu, Chi-Jung
    Hung, Ya-Wen
    Lee, Chieh Ju
    Chi, Chen-Ta
    Lee, I-Cheng
    Yu-Lun, Kuo
    Chou, Shih-Hsuan
    Luo, Jiing-Chyuan
    Hou, Ming-Chih
    Huang, Yi-Hsiang
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (06)
  • [2] Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma
    Abd El Aziz, Mohamed A.
    Facciorusso, Antonio
    Nayfeh, Tarek
    Saadi, Samer
    Elnaggar, Mohamed
    Cotsoglou, Christian
    Sacco, Rodolfo
    VACCINES, 2020, 8 (04) : 1 - 19
  • [3] Association of gut microbiota and metabolites with tumor response to immune checkpoint inhibitors in patients with unresectable hepatocellular carcinoma.
    Lee, Pei-Chang
    Wu, Chi-Jung
    Hung, Ya-Wen
    Lee, Chieh-Ju
    Chao, Yee
    Hou, Ming-Chih
    Kuo, Yu-Lun
    Chou, Shih-Hsuan
    Huang, Yi-Hsiang
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [4] Bile acids, gut microbiota, and therapeutic insights in hepatocellular carcinoma
    Song, Yang
    Lau, Harry C. H.
    Zhang, Xiang
    Yu, Jun
    CANCER BIOLOGY & MEDICINE, 2024, 21 (02) : 144 - 162
  • [5] Bile acids, gut microbiota, and therapeutic insights in hepatocellular carcinoma
    Yang Song
    Harry CH Lau
    Xiang Zhang
    Jun Yu
    Cancer Biology & Medicine, 2024, 21 (02) : 144 - 162
  • [6] Clinical outcomes of immune checkpoint inhibitors in unresectable or metastatic combined hepatocellular–cholangiocarcinoma
    Yoon Jung Jang
    Eo Jin Kim
    Hyung-Don Kim
    Kyu-Pyo Kim
    Min-Hee Ryu
    Sook Ryun Park
    Won-Mook Choi
    Danbi Lee
    Jonggi Choi
    Ju Hyun Shim
    Kang Mo Kim
    Young-Suk Lim
    Han Chu Lee
    Baek-Yeol Ryoo
    Changhoon Yoo
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 7547 - 7555
  • [7] Survival prediction and response to immune checkpoint inhibitors: A prognostic immune signature for hepatocellular carcinoma
    Xu, Ying
    Wang, Zheng
    Li, Fufeng
    TRANSLATIONAL ONCOLOGY, 2021, 14 (01):
  • [8] Impact of gut microbiota on immune modulation and response to immune checkpoint inhibitors in hepatocellular carcinoma: Insights from human and preclinical models
    Rajapakse, Jayashi
    Shen, S. J.
    Khatiwada, Saroj
    Soo, Jason
    Behary, Jason
    Zekry, Amany
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2024, 39 : 53 - 53
  • [9] Clinical outcomes of immune checkpoint inhibitors in unresectable or metastatic combined hepatocellular-cholangiocarcinoma
    Jang, Yoon Jung
    Kim, Eo Jin
    Kim, Hyung-Don
    Kim, Kyu-Pyo
    Ryu, Min-Hee
    Park, Sook Ryun
    Choi, Won-Mook
    Lee, Danbi
    Choi, Jonggi
    Shim, Ju Hyun
    Kim, Kang Mo
    Lim, Young-Suk
    Lee, Han Chu
    Ryoo, Baek-Yeol
    Yoo, Changhoon
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (10) : 7547 - 7555
  • [10] Impact of underlying liver disease on unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors
    Y. Linda Wu
    Sarah Cappuyns
    Amanda Loh
    Sean Sun
    Sara Lewis
    Max W. Sung
    Myron Schwartz
    Josep M. Llovet
    Deirdre J. Cohen
    BJC Reports, 2 (1):
12345